Serum and urinary manganese levels in patients with Parkinson's disease

• Published in: Acta neurologica Scandinavica Vol. 91; no. 5; p. 317
• Main Authors: Jiménez-Jiménez, F J, Molina, J A, Aguilar, M V, Arrieta, F J, Jorge-Santamaría, A, Cabrera-Valdivia, F, Ayuso-Peralta, L, Rabasa, M, Vázquez, A, García-Albea, E
• Format: Journal Article
• Language: English
• Published: Denmark 01-05-1995
• Subjects: Activities of Daily Living - classification; Aged; Brain - drug effects; Brain - physiology; Chromium - adverse effects; Chromium - pharmacokinetics; Cobalt - adverse effects; Cobalt - pharmacokinetics; Female; Humans; Lipid Peroxidation - drug effects; Lipid Peroxidation - physiology; Male; Manganese - adverse effects; Manganese - pharmacokinetics; Metabolic Clearance Rate - physiology; Parkinson Disease - classification; Parkinson Disease - metabolism; Parkinson Disease, Secondary - chemically induced; Parkinson Disease, Secondary - classification; Parkinson Disease, Secondary - metabolism; Receptors, Dopamine - drug effects; Receptors, Dopamine - physiology; Risk Factors
• ISSN: 0001-6314
• DOI: 10.1111/j.1600-0404.1995.tb07014.x

To elucidate the possible role of manganese in the risk of developing Parkinson's disease (PD), we compared serum levels of manganese, and 24-h manganese excretion by urine in 29 PD patients and in 27 matched controls. We also measured chromium and cobalt in the same samples. All these values did not differ significantly between the groups, they were not influenced by antiparkinsonian drugs, and they did not correlate with age, age at onset and duration of the PD, scores of the Unified PD Rating Scale or the Hoehn & Yahr staging in the PD group. These results might suggest that serum levels and urinary excretion of manganese are apparently unrelated to the risk of developing PD.